Introduction
Anti-acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG) is a rare autoimmune disorder characterized by severe muscle weakness. In patients with this disorder, antibodies to the acetylcholine receptor (AChR) can activate the complement cascade, which causes structural damage to the neuromuscular junction (NMJ) [1] [2] [3] . These complement-mediated changes lower the efficiency of neurotransmission at the NMJ resulting in muscle weakness and fatigability that are characteristic of myasthenia gravis (MG) [2] .
In approximately 10-15% of all patients with MG, the signs and symptoms of MG are inadequately controlled by immunosuppressive therapies (ISTs) [4] [5] [6] . In these patients with refractory MG, health-related quality of life and activities of daily living are often significantly impacted, and the risk of experiencing MG crises, exacerbations, hospitalizations, and emergency room visits remains higher than in patients who do respond to ISTs [7, 8] .
Eculizumab is a humanized monoclonal antibody specifically targeted to human terminal complement protein C5 [9] . It is approved in Japan for the treatment of gMG in patients whose symptoms are difficult to control with high-dose intravenous immunoglobulin or plasmapheresis [10] . Its safety and rapid and sustained efficacy in patients with AChR+ refractory gMG have been reported previously [11, 12] .
Differences between the clinical characteristics of MG in Japanese patients and in populations that are mainly Caucasian have been described, particularly with regard to a peak in the incidence of infantile-onset MG, comprising predominantly cases of ocular MG, in Japanese and other Asian populations [13, 14] . Furthermore, different human leukocyte antigen alleles have been associated with age of MG onset [15] and have been reported in Japanese and other Asian patients compared with those seen in Caucasian patients with MG [16, 17] . It is not known whether such differences in genetic background may influence the response of Japanese patients with MG to eculizumab.
A C C E P T E D M A N U S C R I P T
To investigate the efficacy and safety of eculizumab in Japanese patients, we report a subanalysis of interim data from Japanese and Caucasian participants in the open-label extension of the REGAIN study. Caucasian [11] , all non-Japanese, non-Caucasian patients were excluded. Consequently, this sub-analysis reports the efficacy and safety of eculizumab in 11 Japanese and 88
Materials and methods

Study design and study population
Caucasian patients at the 31 December 2017 data cut-off.
For REGAIN, patients were randomized to receive placebo or eculizumab, with stratification according to Myasthenia Gravis Foundation of America classification at screening; patients were not randomized within countries or centers because the numbers of patients for each location were anticipated to be low [11] . Full REGAIN inclusion and exclusion criteria have been reported [11] . Key inclusion criteria were: confirmed gMG with a positive serologic test result for anti-AChR antibodies; a total score on the Myasthenia Gravis Activities of Daily
Living scale (MG-ADL) of 6 or higher; and received and failed treatment with two or more ISTs, or with one or more ISTs and chronic plasma exchange therapy or intravenous immunoglobulin at least four times over the previous 12 months. A history of thymoma or other thymic neoplasms was a key criterion for exclusion. Patients were required to have been vaccinated against Neisseria meningitidis. During REGAIN, patients previously
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receiving ISTs were required to maintain their pre-study dose and schedule; in the openlabel study, adjustment of concomitant ISTs was permitted at the discretion of the investigator. However, adjustment of ISTs was not required by the study protocol or requested by the sponsor.
Written informed consent was obtained from all patients before entering the open-label study. The study was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the appropriate ethics committee for each study site. 
Dosing and administration of eculizumab
Assessments
This sub-analysis presents open-label study data for the period up to 52 weeks. [21] . MG-ADL, QMG, and MGC were assessed at day 1 and also weekly to week 4; MG-QoL15 was assessed at day 1 and then at week 4. All four assessments were performed at weeks 8, 12, 16, 20, 26, A C C E P T E D M A N U S C R I P T 40, and 52 in year 1, and then every 6 months or at termination if this was before the study ended.
In or requirement for rescue therapy.
Statistical analysis
Efficacy analyses were conducted using data from Japanese and Caucasian patients in the full analysis set, which comprised all patients who received at least one dose of eculizumab in the open-label study and had at least one post-infusion efficacy assessment. Safety analyses were performed using the safety set (all patients who received at least one dose of eculizumab in the open-label study). imputed. This sub-analysis provides descriptive statistics for Japanese and Caucasian patients in the placebo/eculizumab group; because the number of Japanese patients in the eculizumab/eculizumab group was low, data for this group were not separated by race. Data are reported as means and corresponding standard error of the means.
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Results
Demographic and disease characteristics
As of 31 December 2017, a total of 117 patients had enrolled into the open-label study and had received at least one dose of eculizumab. Eighteen patients who were neither Japanese nor Caucasian were excluded from this sub-analysis (eight were Asian but not Japanese, two black, six of other race, one of multiple races, and one of unknown race America; 41 received placebo and 47 received eculizumab during REGAIN). The male/female ratio and age at first study drug dose were similar for Japanese and Caucasian
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patients, although Japanese patients tended to weigh less than Caucasian patients (Table 1) . Disease burden, evaluated by MG-ADL, QMG, MGC, and MG-QoL15 scores and MGFA classification, in each group at open-label baseline is presented in Table 1 .
In this interim sub-analysis of the extension study, all eight Japanese patients and 36/41
Caucasian patients (88%) in the placebo/eculizumab group had received eculizumab for at least 52 weeks. In the eculizumab/eculizumab group, 43/50 patients (86%) had received eculizumab for at least 52 weeks in the open-label study; therefore, the majority of patients in this group had received eculizumab for at least 78 weeks (including 26 weeks' treatment in REGAIN).
Efficacy analyses
Changes from open-label extension study and REGAIN baselines for the Japanese and Caucasian placebo/eculizumab groups
During the 26-week REGAIN study, some degree of placebo response was observed, and the eight Japanese patients showed a stronger placebo response than the Caucasian patients, especially for changes in mean MG-ADL, MGC, and MG-QoL15 total scores (Fig. 1) . During the open-label study blinded-induction phase, the Japanese patients in the placebo/eculizumab group generally had rapid improvements in response to eculizumab in mean MG-ADL, QMG, MGC, and MG-QoL15 total scores (Fig. 1, Fig. 2) . The placebo/eculizumab-treated Caucasian patients also had rapid responses to eculizumab during the induction phase. While the change from REGAIN baseline was greater in the Japanese patients than in Caucasian patients (Fig. 1) , the change from open-label baseline was similar between the two groups (Fig. 2) . Improvements in all measures were sustained through 52 weeks. The patterns of improvements with eculizumab in the open-label study observed for these patients in the placebo/eculizumab group were also similar to those observed for eculizumab-treated patients in REGAIN. 
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Changes from open-label extension study and REGAIN baselines for the eculizumab/eculizumab-treated patients
For the eculizumab/eculizumab group (Japanese and Caucasian patients together), the improvements seen during REGAIN were sustained through 52 weeks during the open-label study ( Fig. 1, Fig. 2 
Safety analyses
In total, 99 patients were included in the safety analysis set ( Table 2 ). The most frequently reported adverse events were headache (36.4% of Japanese patients, 37.5% of Caucasian patients) and nasopharyngitis (100.0% of Japanese patients, 23.9% of Caucasian patients).
At the time of this sub-analysis, serious adverse events were experienced by 45.5% of Japanese patients (5/11; four in the placebo/eculizumab group and one in the eculizumab/eculizumab group) and 46.6% of Caucasian patients (41/88; 19 in the placebo/eculizumab group and 22 in the eculizumab/eculizumab group; Table 3 , and 
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10 Caucasian patients; eculizumab/eculizumab group: 2 Japanese patients and 9 Caucasian patients; Table 2 ). One Japanese patient in each treatment group withdrew from the study and one in the eculizumab/eculizumab group was withdrawn by their physician. No Japanese patients discontinued owing to adverse events, and no deaths were reported through week 52. Eight Caucasian patients elected to withdraw from the study, and 4 were withdrawn by their physician (placebo/eculizumab group: 6 and 2, respectively; eculizumab/eculizumab group: 2 and 2, respectively). In addition, three Caucasian patients discontinued owing to serious adverse events: one discontinuation was due to MG clinical deterioration (placebo/eculizumab group), one was due to MG crisis, and one was due to rectal abscess. One additional patient discontinued for a reason recorded as 'other'
(eculizumab/eculizumab group).
Three Caucasian patients died; all had comorbidities that were likely to have contributed to these outcomes. The first death (in the eculizumab/eculizumab group) occurred in a patient who was receiving concomitant azathioprine, and was attributed to hemophagocytic lymphohistiocytosis associated with cytomegalovirus infection of the liver resulting in hepatic failure and multi-organ failure. This death was considered by the investigator to be probably related to study treatment. The second death from pulmonary embolism (placebo/eculizumab group) occurred in a hospitalized patient who had a history of pulmonary disease, and was recovering from cardiogenic shock secondary to sepsis, which was complicated by a deep vein thrombosis. The third death (eculizumab/eculizumab group) was attributed to end-stage liver disease in a patient with a history of liver disease including fatty liver and cryptogenic liver cirrhosis. The latter two deaths were considered by the investigators to be unlikely to be related to study treatment.
Exacerbations were experienced by 27.3% of Japanese patients and 18.2% of Caucasian patients. Hospitalization related to worsening of MG was required by 36.4% of Japanese patients and 10.2% of Caucasian patients. No meningococcal infections occurred as of the
interim analysis cut-off date; one case occurred after this date in a Caucasian female patient who received antibiotics and recovered.
Discussion
Published data suggest that the prevalence of MG in Japan increased between 1987 and 2006 [13] , possibly owing to improvements in diagnostic accuracy and patient follow-up, as well as increased longevity. Another survey (1999) (2000) showed that up to 70% of Japanese patients with MG who had received standard treatment had persistent ocular or generalized weakness that may result in moderate or severe disability [23] . The Japanese guidelines for MG treatment were updated in 2014 to emphasize the importance of patients' quality of life [24] [25] [26] . These changes were informed by a large retrospective analysis of Japanese patients with MG that evaluated factors impacting on quality of life, and recommended using early, fast-acting treatment strategies [27] . Such treatment strategies have demonstrated improved outcomes for Japanese patients compared with other approaches using conventional therapies; however, these strategies are not effective for all patients [27] , suggesting that new, innovative treatment approaches would be of benefit in these patients.
The safety and rapid and sustained efficacy of the terminal complement inhibitor eculizumab have been demonstrated in the phase 3 REGAIN study and its open-label extension in an international population of patients with AChR+ refractory gMG [11, 12] . It is possible that previously described differences in clinical and genetic characteristics between Japanese and Caucasian patients with MG [13, 16, 17] may impact the immunopathogenesis of MG and thus influence patients' responses to therapy. We have therefore investigated the efficacy and safety of eculizumab in Japanese patients with refractory gMG in the REGAIN open-label extension study.
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This sub-analysis of interim data from the REGAIN open-label extension study has shown that the rapid and sustained improvements observed during eculizumab treatment in REGAIN [11] , and during the open-label study in Caucasian patients who had received placebo during REGAIN, were also seen in the small number of Japanese patients who commenced eculizumab therapy at the start of the open-label study. Notably, over half of both Japanese and Caucasian patients who had refractory gMG at the start of REGAIN achieved minimal manifestations of MG after 52 weeks of open-label eculizumab therapy.
The placebo effect observed in the REGAIN study has been discussed previously, and could have been influenced by factors such as more frequent follow-up in the study than in usual clinical practice, or the expected variability of MG symptoms over time [11] . Interestingly, the eight Japanese patients who received placebo for 26 weeks in REGAIN exhibited a stronger placebo response than that experienced by Caucasian patients in the placebo group. The reasons for this difference are not known, but there was more variability in response in the Japanese patients than in the Caucasian patients, probably owing to the small number of Japanese patients overall. On commencement of eculizumab therapy after receiving placebo during REGAIN, improvements during the blinded-induction phase and up to 52 weeks in the maintenance phase of the open-label study were of similar magnitude in Japanese and Caucasian patients.
The safety profiles of eculizumab in Japanese and Caucasian patients during the open-label study were consistent with those reported for eculizumab-treated patients in REGAIN [11] and in studies in atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria [28] [29] [30] . No new safety concerns were identified in Japanese participants.
No meningococcal infections occurred during this interim analysis period; one case occurred after this in a Caucasian patient who recovered [12] . The three patients who died during the open-label extension were Caucasian [12] .
A limitation of this sub-analysis is the low number of Japanese patients, who constituted a relatively small proportion ( Table 1 Baseline demographics and disease characteristics of Japanese and Caucasian patients in the open-label extension study. A C C E P T E D M A N U S C R I P T Table 2 Safety information for all Japanese and Caucasian patients in the open-label study. A C C E P T E D M A N U S C R I P T 
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